title: Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves.
abstract: Here, we show that extracorporeal shock waves (ESW), at a low energy density value, quickly increase neuronal nitric oxide synthase (nNOS) activity and basal nitric oxide (NO) production in the rat glioma cell line C6. In addition, the treatment of C6 cells with ESW reverts the decrease of nNOS activity and NO production induced by a mixture of lipopolysaccharides (LPS), interferon-gamma (IFN-gamma) plus tumour necrosis factor-alpha (TNF-alpha). Finally, ESW treatment efficiently downregulates NF-kappaB activation and NF-kappaB-dependent gene expression, including inducible NOS and TNF-alpha. The present report suggests a possible molecular mechanism of the anti-inflammatory action of ESW treatment.
authors.affiliation: Dipartimento di Scienze Neurologiche e della Visione, Sezione di Chimica Biologica, Università degli Studi di Verona, Strada Le Grazie, 8, 37134 Verona, Italy.
authors.forename: Anna R
authors.initials: AR
authors.lastname: Ciampa
authors.forename: Alessandra Carcereri
authors.initials: AC
authors.lastname: de Prati
authors.forename: Ernesto
authors.initials: E
authors.lastname: Amelio
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Cavalieri
authors.forename: Tiziana
authors.initials: T
authors.lastname: Persichini
authors.forename: Marco
authors.initials: M
authors.lastname: Colasanti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Musci
authors.forename: Ernst
authors.initials: E
authors.lastname: Marlinghaus
authors.forename: Hisanori
authors.initials: H
authors.lastname: Suzuki
authors.forename: Sofia
authors.initials: S
authors.lastname: Mariotto
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D045424:Complex Mixtures / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D015971:Gene Expression Regulation, Enzymologic / Q000528:radiation effects*; D005910:Glioma / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D019220:High-Energy Shock Waves / Q000627:therapeutic use*; D007249:Inflammation / Q000628:therapy*; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D018613:Microscopy, Confocal; D009474:Neurons / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D045424:Complex Mixtures; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II